Proteins & Antibodies Sponsors 2015

  • Absolute Antibody

    Absolute Antibody is a CRO offering fully customised services for the sequencing, engineering and manufacture of antibodies. Located across two sites in the UK, Absolute Antibody is a recently established company run by a leadership team with a wealth of experience in the development and manufacture of therapeutic antibodies. We focus on making the production of milligram to gram quantities of antibody quicker and more cost effective for early to mid-stage therapeutic projects through the use of proprietary vectors (pUV™), a high-yielding transient mammalian cell line (ABS293™) and a universal purification platform. For early stage projects we offer a variant screening service for cloning and production of microgram to milligram quantities of as many as 96 antibodies in parallel. For later stage projects we offer rapid manufacture of almost any antibody format, such as IgG, Fab and Fab2, up to gram quantities with high purity and low endotoxin suitable for all in vitro and in vivo uses.

  • Agilent Technologies

  • Aldevron

    Aldevron provides custom plasmid DNA manufacturing to support many gene and cell therapy applications. With our experience and scientific expertise, we have developed screening strategies to optimize yield and stability of even the most challenging vector plasmids. We also provide consistency at all levels, with a deliberate pathway from research to clinical requirements.  Visit with our team to learn about our additional services including, mRNA, protein production, gene synthesis and antibody development. Aldevron's mission is to advance science, and we have solutions that are designed for you.

  • Avia Biosystems

    AVIA Logo 2C


    AVIA Biosystems is helping Bio-Pharmaceutical companies gain critical insights about Protein Stability to advance the best molecules faster, fail challenging molecules sooner, and optimize formulation and process conditions, potentially saving millions of dollars in financial and human resources for their businesses.
    AVIA Biosystems has developed the first automated ICD (Isothermal Chemical Denaturation) Systems to the biopharmaceutical industry.  These systems provide simultaneous determination of protein stability and aggregation at temperatures meaningful to the processing and long-term storage of therapeutic proteins.  ICD systems are utilized at multiple stages in the biologics development process including protein construct stability rank-ordering, process conditions optimization, pre-formulations screening and formulations optimization.  In early stage development, ICD data contributes significantly to the developability assessment of new biologics.  In later stage development, ICD data enables quantitative, thermodynamically directed, formulations optimization.  ICD provides valuable insights and guidance about the compromises between protein conformational stability, solubility and viscosity that need to be addressed during formulations optimization.  The optimal biologic formulation is the one that provides optimal long-term stability and ICD is able to provide quantitative guidance throughout the formulation optimization process by measuring protein stability, native protein self-association and denatured protein aggregation as a function of formulation buffer and excipient conditions.

  • Blirt


    Blirt is the leading provider of comprehensive, high quality non-GMP recombinant proteins and bio-manufacturing services in Poland. With over 6 years of experience in recombinant protein production and a team of in-house experts specializing in E. coli, yeast and mammalian expression, we have succeeded in over 200 projects done for numerous pharma and biotech clients, including long-term Big Pharma collaboration for non-GMP proteins for R&D use.

    Our services cover:

    • Protein production
    • Monoclonal & polyclonal antibody production (as part of comprehensive projects)
    • Cell Line Development
    • Recombinant IgG production
    • SPR Services
  • Chelatec


  • Cobra Bio

    Cobra bio NO strapline

    Cobra provide a comprehensive biologics and pharmaceuticals service offering, with multi-functional and experienced project teams nurturing customers products through to clinical and commercial manufacture within three GMP approved facilities. Expertise: Cobra are a Contract Manufacturing Organisation (CMO) supporting the global life sciences industry in the development and manufacture of monoclonal antibodies (mAb), recombinant proteins, DNA, viruses, phage and cell line derived products and pharmaceuticals for clinical trials and commercial supply. Experience: Over 15 years of track record in producing biologics and pharmaceuticals for use in pre-clinical to Phase III clinical trials and commercial supply has given our people a unique knowledge base as both manufacturer and also as service providers for the global life sciences market.We offer a broad range of integrated and stand-alone development services, stretching from cell line development to the supply of investigational medicinal product for clinical trials and commercial market supply. Excellence: Every program complies with cGMP standards worldwide and is conceived with an unmatched quality derived from the know-how of Cobra’s highly qualified, flexible and dedicated people.

  • DNA 2.0

    DNA2.0 is the leading bioengineering solutions provider. Founded in 2003, DNA2.0 provides an integrated pipeline of solutions for the research community, including gene design, optimization, synthesis and cloning, as well as platforms for protein and strain engineering. It is the fastest provider of synthetic genes—based in the US with a global customer base encompassing academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries. DNA2.0 is by far the most published synthetic gene vendor, providing expert support to and collaboration with scientists. DNA2.0 explores novel applications for synthetic genes and is exploiting the synergy between highly efficient gene design and synthesis processes and new protein optimization technologies. DNA2.0’s tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. The company is privately held and is headquartered in Menlo Park, California.

  • Euro Technologies



  • Eurogentec

  • Fujifilm Diosynth Biotechnologies

    25453 fuji logo NEW

    FUJIFILM Diosynth Biotechnologies is an industry leading Biologics Contract Development and Manufacturing Organisation with locations in Billingham, United Kingdom and Research Triangle Park, North Carolina, USA.  Between them the two sites have received successful FDA inspections for the manufacture of a total of five commercial products across a range of microbial and cell culture based biologics.
    Long recognised as a world leader in the process development and manufacture of microbial-derived biologics, the company has significantly expanded its mammalian cell culture capabilities in the last two years.  A new mammalian cell culture manufacturing facility was commissioned in October 2013 at the Billingham, UK site; this has been designed primarily to utilise single-use technologies, with the initial installation of a 1000L single-use bioreactor, with a 2000L bioreactor installed in late 2014 to meet customer demand.  This facility complements 1000L and 2000L single-use bioreactors at the company’s RTP plant.  

  • Ibis Technologies

    logo IBIS nieuw


  • Malvern


  • Roche


  • Schrodinger

  • Sigma-Aldrich

  • TSI


  • Xpress Biologics


    Xpress Biologics is a biotech company proposing contract services for the production of recombinant proteins, antibody fragments and plasmid DNA for preclinical applications specific to the therapeutic and diagnostic markets (human & veterinary).
    Its mission is to enable the transition of the projects from R&D to clinical manufacturing.
    The production scale (from 100 mg up to several tens of grams) and the quality of the biologics (R&D and GLP grade material) proposed by Xpress Biologics are adapted for in vitro and in vivo pre-clinical validation of the biologics (proof-of-concept, early safety, potency, efficacy…).
    The production processes are all developed in microbial expression systems, E. coli (soluble cytoplasmic, inclusion bodies and periplasmic productions) and P. pastoris (secreted protein) mainly.
    Moreover, Xpress Biologics processes are free of charge in terms of license or royalty fees and take into account the industrial (scale-up) and regulatory requirements, including the development of the quality controls, which greatly facilitates the transfer of the project to CMOs (Contract Manufacturing Organizations) for the production of GMP grade material.
    Xpress Biologics acts as One-Stop-Shop and can, through project management with defined subcontractors, take in charge additional services as the production of GMP grade material, the organization of pre-clinical and clinical studies.